Predictive Factors of Early Progression After CAR T-Cell Therapy in Relapsed/Refractory DLBCL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Predictive Factors of Early Progression After CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Blood Adv 2020 Nov 24;4(22)5607-5615, L Vercellino, R Di Blasi, S Kanoun, B Tessoulin, C Rossi, M D'Aveni-Piney, L Obéric, C Bodet-Milin, P Bories, P Olivier, I Lafon, A Berriolo-Riedinger, E Galli, S Bernard, MT Rubio, C Bossard, V Meignin, P Merlet, P Feugier, S Le Gouill, L Ysebaert, O Casasnovas, M Meignan, S Chevret, C ThieblemontFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.